Abstract
Mouse models of multiple myeloma (MM) are basic tools for translational research and play a fundamental role in the development of new therapeutics against plasma cell malignancies. All available models, including transplantable murine tumors in syngenic mice, xenografts of established human cell lines in immunocompromised mice and transgenic models that mirror specific steps of MM pathogenesis, have demonstrated some weaknesses in predicting clinical results, particularly for new drugs targeting the human bone marrow microenvironment (huBMM). The recent interest to models recapitulating the in vivo growth of primary MM cells in a human (SCID-hu) or humanized (SCID-synth-hu) host recipient has provided powerful platforms for the investigation of new compounds targeting MM and/or its huBMM. Here, we review and discuss strengths and weaknesses of the key in vivo models that are currently utilized in the MM preclinical investigation.
Keywords: Microenvironment, mouse models, multiple myeloma, scaffolds, SCID-hu, SCID-rab, SCID-synth-hu, 5TMM, Bone marrow microenvironment, Bone marrow stromal cells, Non–obese diabetic.
Current Cancer Drug Targets
Title:Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
Volume: 12 Issue: 7
Author(s): P. Tassone, P. Neri, R. Burger, M. T. Di Martino, E. Leone, N. Amodio, M. Caraglia and P. Tagliaferri
Affiliation:
Keywords: Microenvironment, mouse models, multiple myeloma, scaffolds, SCID-hu, SCID-rab, SCID-synth-hu, 5TMM, Bone marrow microenvironment, Bone marrow stromal cells, Non–obese diabetic.
Abstract: Mouse models of multiple myeloma (MM) are basic tools for translational research and play a fundamental role in the development of new therapeutics against plasma cell malignancies. All available models, including transplantable murine tumors in syngenic mice, xenografts of established human cell lines in immunocompromised mice and transgenic models that mirror specific steps of MM pathogenesis, have demonstrated some weaknesses in predicting clinical results, particularly for new drugs targeting the human bone marrow microenvironment (huBMM). The recent interest to models recapitulating the in vivo growth of primary MM cells in a human (SCID-hu) or humanized (SCID-synth-hu) host recipient has provided powerful platforms for the investigation of new compounds targeting MM and/or its huBMM. Here, we review and discuss strengths and weaknesses of the key in vivo models that are currently utilized in the MM preclinical investigation.
Export Options
About this article
Cite this article as:
Tassone P., Neri P., Burger R., T. Di Martino M., Leone E., Amodio N., Caraglia M. and Tagliaferri P., Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429292
DOI https://dx.doi.org/10.2174/156800912802429292 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Phenotyping of Mouse Mutant Resources by RNA Expression Profiling
Current Genomics Advances in Computational Structure-Based Drug Design and Application in Drug Discovery
Current Topics in Medicinal Chemistry Bioconjugation of Ionophore Antibiotics: A Way to Obtain Hybrids with Potent Biological Activity
Mini-Reviews in Organic Chemistry CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Novel Virally Targeted Therapies of EBV-Associated Tumors
Current Cancer Drug Targets Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry In-silico Evidences of Regulatory Roles of WT1 Transcription Factor Binding Sites on the Intervening Sequences of the Human Bcl-2 Gene
Current Bioinformatics Electrocatalytic Determination of 6-Mercaptopurine Using Multiwall Carbon Nanotubes Paste Electrode in the Presence of Methyldopa
Current Nanoscience Discriminating Ramos and Jurkat Cells with Image Textures from Diffraction Imaging Flow Cytometry Based on a Support Vector Machine
Current Bioinformatics Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
Clinical Cancer Drugs Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study
Current Drug Targets The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Innate and Adaptive Immune Responses in Allergic Contact Dermatitis and Autoimmune Skin Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Diagnosis and Therapy of Autoimmune Hepatitis
Mini-Reviews in Medicinal Chemistry Chemical Diversity and Bioactivity of Marine Sponges of the Genus Oceanapia: A Review
Mini-Reviews in Organic Chemistry